Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alimera Sciences Inc (ALIM)

Alimera Sciences Inc (ALIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,693
  • Shares Outstanding, K 5,032
  • Annual Sales, $ 53,940 K
  • Annual Income, $ -10,440 K
  • 60-Month Beta 1.99
  • Price/Sales 0.43
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALIM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.49
  • Number of Estimates 1
  • High Estimate -0.49
  • Low Estimate -0.49
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +18.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 unch
on 10/23/20
5.45 -17.25%
on 09/29/20
-0.51 (-10.16%)
since 09/23/20
3-Month
4.51 unch
on 10/23/20
8.06 -44.04%
on 08/05/20
-1.46 (-24.46%)
since 07/23/20
52-Week
2.86 +57.68%
on 03/19/20
9.98 -54.81%
on 12/10/19
-1.04 (-18.74%)
since 10/23/19

Most Recent Stories

More News
Ocular Inflammation Treatment Market Research Services Industry to 2025 – COVID-19 Impact and Recovery

The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

AKRX : 0.0900 (-51.01%)
ALIM : 4.51 (-2.17%)
AGN : 193.02 (+0.02%)
NVS : 84.43 (+0.02%)
PFE : 38.18 (+2.00%)
VRX.TO : 30.80 (-3.33%)
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update

Alimera Sciences, Inc. (Nasdaq: ALIM) ("Alimera" or the "Company"), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces...

ALIM : 4.51 (-2.17%)
Diabetic retinopathy Market Set for Rapid Growth forecast 2020-2026| Key Players – Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., and more

The latest updated report on the added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates...

ABT : 107.79 (-1.54%)
ALIM : 4.51 (-2.17%)
AMPE : 0.8134 (-0.80%)
BAYRY : 12.5000 (+0.16%)
NVS : 84.43 (+0.02%)
PRXL : 88.08 (-0.02%)
PFE : 38.18 (+2.00%)
REGN : 579.81 (+0.71%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market 2020 Analysis by Top Manufacturers -Allergan Plc., Cipla Ltd., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals International, Inc., Alimera Sciences

AKRX : 0.0900 (-51.01%)
ALIM : 4.51 (-2.17%)
AGN : 193.02 (+0.02%)
NVS : 84.43 (+0.02%)
PFE : 38.18 (+2.00%)
VRX.TO : 30.80 (-3.33%)
Ocular Drug Delivery Technology Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The Global is estimated to value over USD 19 billion by 2027 end with a CAGR of over 6.8% during the forecast period 2020 to 2027.

ALIM : 4.51 (-2.17%)
AGN : 193.02 (+0.02%)
SNPHF : 20.1500 (+1.51%)
VRX.TO : 30.80 (-3.33%)
Diabetic Retinopathy Market 2020-2026 Exhibit A Huge Growth By Profiling Major Companies: Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., and more

The latest updated report on the added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates...

ABT : 107.79 (-1.54%)
ALIM : 4.51 (-2.17%)
AMPE : 0.8134 (-0.80%)
BAYRY : 12.5000 (+0.16%)
NVS : 84.43 (+0.02%)
PRXL : 88.08 (-0.02%)
PFE : 38.18 (+2.00%)
REGN : 579.81 (+0.71%)
VRX.TO : 30.80 (-3.33%)
Alexion's Ultomiris Gets Approval in Japan for Rare Disease

Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.

ALXN : 121.61 (+1.62%)
EBS : 96.11 (-1.58%)
ALIM : 4.51 (-2.17%)
TECH : 268.46 (-0.45%)
Global Ocular Drug Delivery Technology Market Phenomenal Growth, Revenue and Potential Targets (2020-2029) | OCULAR THERAPEUTIX, Alimera Sciences, Allergan

for the forecast year 2020-2029, which is beneficial for companies regardless of their size and revenue. This Survey report covering the major market insights and industry approach towards COVID-19 in...

A : 106.17 (-0.56%)
ALIM : 4.51 (-2.17%)
AGN : 193.02 (+0.02%)
BMY : 60.13 (-1.04%)
MDSY : 0.73 (+4.29%)
NVS : 84.43 (+0.02%)
OCUL : 10.18 (-1.40%)
STLB : 0.0001 (unch)
VRX.TO : 30.80 (-3.33%)
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN(R) To Be Presented at the EURETINA 2020 Virtual Congress

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical...

ALIM : 4.51 (-2.17%)
Global Ocular Inflammation Treatment Market 2020 Future Trend, Business Strategies, Revenue Value, Comprehensive Analysis and Forecast by 2025

offers a detailed sketch of each segment with sub-segment of the global market. The report depicts information regarding the drivers, restraints, opportunities, and trends affecting the global Ocular Inflammation...

AKRX : 0.0900 (-51.01%)
ALIM : 4.51 (-2.17%)
NVS : 84.43 (+0.02%)
PFE : 38.18 (+2.00%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes...

See More

Key Turning Points

2nd Resistance Point 4.76
1st Resistance Point 4.64
Last Price 4.51
1st Support Level 4.45
2nd Support Level 4.38

See More

52-Week High 9.98
Fibonacci 61.8% 7.26
Fibonacci 50% 6.42
Fibonacci 38.2% 5.58
Last Price 4.51
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar